Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice - Wikidata - wikimedia - TriplyDB

Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice

Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice

http://www.wikidata.org/entity/Q30479999

about

PRTFDC1 is a genetic modifier of HPRT-deficiency in the mouse Radiosynthesis and first preclinical evaluation of the novel norepinephrine transporter pet-ligand [(11)C]ME@HAPTHI A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease Human Bacterial Artificial Chromosome (BAC) Transgenesis Fully Rescues Noradrenergic Function in Dopamine β-Hydroxylase Knockout Mice Role of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons.Manganese-induced atypical parkinsonism is associated with altered Basal Ganglia activity and changes in tissue levels of monoamines in the rat β1-Adrenergic receptors activate two distinct signaling pathways in striatal neurons Norepinephrine is required to promote wakefulness and for hypocretin-induced arousal in zebrafish.Norepinephrine modulates the motility of resting and activated microglia via different adrenergic receptors.Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons.Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice Behavioral phenotyping of mouse models of Parkinson's disease.Neurophysiological Changes Induced by Chronic Toxoplasma gondii Infection Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.Noradrenergic regulation of glial activation: molecular mechanisms and therapeutic implications.L-DOPA reverses motor deficits associated with normal aging in mice.Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease Electro-acupuncture stimulation improves spontaneous locomotor hyperactivity in MPTP intoxicated mice Tongue force and timing deficits in a rat model of Parkinson disease.Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.Chronic loss of noradrenergic tone produces β-arrestin2-mediated cocaine hypersensitivity and alters cellular D2 responses in the nucleus accumbens Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons.Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo Apoptosis-inducing factor in nigral dopamine neurons: Higher levels in primates than in mice.Lesioning noradrenergic neurons of the locus coeruleus in C57Bl/6 mice with unilateral 6-hydroxydopamine injection, to assess molecular, electrophysiological and biochemical changes in noradrenergic signaling.The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities Sequential Loss of LC Noradrenergic and Dopaminergic Neurons Results in a Correlation of Dopaminergic Neuronal Number to Striatal Dopamine Concentration.Dietary energy intake modifies brainstem autonomic dysfunction caused by mutant α-synuclein.Specificity and impact of adrenergic projections to the midbrain dopamine system.Behavioral responses of dopamine beta-hydroxylase knockout mice to modafinil suggest a dual noradrenergic-dopaminergic mechanism of action.Dopamine signaling in the dorsal striatum is essential for motivated behaviors: lessons from dopamine-deficient mice.Light and electron microscopic localization of alpha-1 adrenergic receptor immunoreactivity in the rat striatum and ventral midbrain alpha(1A)- and alpha(1B)-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse.Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model of Parkinson's disease.Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.Advances in non-dopaminergic treatments for Parkinson's disease

P2860

Q21135297-B3526F1D-BA50-4AD7-8E0A-A87A92B60350 Q21999407-CC4740FE-4B8F-4A1E-8E47-4714033B681B Q26859072-A377C5E9-041A-4272-90FE-396D4740892A Q27334826-F427D178-F553-451B-AB05-D07B79159BF6 Q28115881-0E12094D-7CFC-4FFE-909C-71A93D276155 Q28395100-36360507-6BD1-4FDF-B073-B2F849C87F32 Q28539360-A969FCF3-7784-470B-A8FA-4FD03BBFEFD6 Q28581364-D36AA1A1-4C61-4DBC-AFA6-6938893F7146 Q30401043-6A97243B-CF09-46BD-AD6B-9DB00F58B7E3 Q30540053-FD8B905A-4BEC-4BD6-AFAA-6F2912B1517B Q33312931-F51350FF-E058-4595-9D39-751B1253CF6A Q33507513-1BEE8303-38CA-4B9D-9B99-E8E1529A7B15 Q33680232-2C297453-6406-43F0-B5F7-2D55123DEFD4 Q33820609-74A1C1A7-BEF1-4AC1-B00C-0910A231BCE7 Q33847259-68936EE2-B357-4998-BAAC-CB4ABE1B2D32 Q33918393-FB59B28D-C411-494A-AD12-BA92964B57DC Q34391616-6791E8B7-62F5-45FE-B1B0-8B6AFE80C008 Q34482342-25CFC833-FB45-4D8A-AF21-4AA14622AFE8 Q34572608-6ACC5358-1047-46B2-AFB0-60390D04839A Q34758776-0CB517B5-747B-433E-BAFE-CB8C460FD221 Q35041340-6EEC2F37-0D6F-4497-B6C3-5B660ABD0C09 Q35065682-92C4B4E4-CEC5-4930-B2F6-3B84BD304DB3 Q35079713-A0DC3DA6-8299-4F45-9547-41BB53BE5CF7 Q35167964-1058EDA0-7512-47E8-8066-C47AFFE15FAD Q35624275-37E12D1F-5194-40A7-9117-3C98CEFF750D Q35912064-6C8D00C4-2866-4950-B5F6-547F9B1851DD Q36051152-0D4C1E5F-7408-4D11-B491-B0DDBA77A21D Q36060314-25D9E0CE-5FC1-46F8-8364-B16A4B901D76 Q36305967-702B5520-F23C-4A11-8203-8333A57C1988 Q36366780-DD78D5A3-725F-416F-8C6D-3B6446F2B1B3 Q36400251-A6427506-899B-4098-9045-5E83A87079E6 Q36932568-096193BF-D889-4536-A727-552BE92AB579 Q37003897-B8A8B3FD-A5DA-4202-B57E-FE4D8894D1A6 Q37203759-73241505-AF1C-4C4B-A3DD-FF2044F7B5EF Q37217480-FB3BF1F3-929E-47A7-B1BF-720D3B82918E Q37288164-B0DE02C9-5858-436B-9126-CCBF30DA0298 Q37395632-00443DE1-C92A-4E15-BE95-811F630F8F3B Q37399627-609F4E77-7500-4290-AB5A-18988BD7697F Q37880260-14849748-F1FF-4F6D-A5E4-47B85AC15534 Q38218083-D810022C-551D-4556-B8DC-720454B62B37

P2860

Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice

http://www.wikidata.org/entity/Q30479999

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice

@ast

Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice

@en

type

label

Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice

@ast

Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice

@en

prefLabel

Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice

@ast

Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice

@en

P1433

Q30479999-054D52D7-D509-4923-9C06-D0321DA75C49

P1476

Q30479999-0C52F3FD-6C42-493C-B476-545FB1A9101D

P2093

Q30479999-090F263C-347C-49AC-A19A-ECEF3DCE186D

Q30479999-21E4F22A-D3FD-4BB9-BABF-EE08FC3EB3BC

Q30479999-380E8271-0D2D-4018-AE6D-B5B9F574375E

Q30479999-75A0BB51-4172-49C8-BC81-D09B08340E6F

Q30479999-8C06B016-47F9-4AC4-966F-56972452D3FA

Q30479999-95F21E67-A338-45F4-89DD-FAFCDBB533CE

P2860

Q30479999-00F9372D-D03C-48F0-9946-C1AA63944600

Q30479999-011A4AC5-E9C1-4948-AFC7-69F5951B174E

Q30479999-026FB3C2-ED07-4C68-BE8F-6B40C02959CA

Q30479999-041F7207-56B5-4D73-A59F-A65F2033F8E9

Q30479999-096B3107-2D72-4F0F-B4BE-6FEB5149330D

Q30479999-0BAF3A36-1DB7-48C6-9D9A-E7DD844F0243

Q30479999-0DA7B566-1CAF-4111-B5F6-1E58E1EB7034

Q30479999-0DC44836-408B-46CC-96B1-775645135D56

Q30479999-24D935B8-E2DF-49E5-8101-57D8F2C539D1

Q30479999-36026581-A61E-46B3-AC16-505650243516

P304

Q30479999-23F55ACB-D4F1-44D1-9879-E720EDF2DF65

P31

Q30479999-BEAE4930-2C92-4D2C-ACED-CA968B0138F0

P356

Q30479999-E756C83A-D636-4A0B-A53F-595F76D447F6

P407

Q30479999-FCEE0C27-8432-41AA-8D21-038307EB8CF2

P433

Q30479999-2681A144-660E-43D3-9B86-0A03A6461994

P478

Q30479999-D93E2795-3529-4CEC-8E87-0774A64B4A16

P577

Q30479999-00E78916-4055-4D37-B542-CBEAC1482FE0

P5875

Q30479999-D6EDE5B1-6B9B-4FB4-89DB-0049819F4F8D

P698

Q30479999-B15DDC84-3DCA-46F0-83C6-CB3FBC8DF4B6

P921

Q30479999-bf396d18-919a-4737-b7a0-b850c1642e4b

P932

Q30479999-14FC963F-DF51-487F-B105-38A8F44481DB

P356

PNAS.0702753104

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice

@en

P2093

D Weinshenker

http://www.w3.org/2001/XMLSchema#string

G L Edwards

http://www.w3.org/2001/XMLSchema#string

G W Miller

http://www.w3.org/2001/XMLSchema#string

K G Freeman

http://www.w3.org/2001/XMLSchema#string

K S Rommelfanger

http://www.w3.org/2001/XMLSchema#string

L C Liles

http://www.w3.org/2001/XMLSchema#string

P2860

Staging of brain pathology related to sporadic Parkinson's disease

A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus

Mice with chronic norepinephrine deficiency resemble amphetamine-sensitized animals

Noradrenaline is essential for mouse fetal development

Restoration of norepinephrine and reversal of phenotypes in mice lacking dopamine beta-hydroxylase

Epidemiology of Parkinson's disease

Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.

Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons.

Biochemical effects of the monoamine neurotoxins DSP-4 and MDMA in specific brain regions of MAO-B-deficient mice.

D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.

P304

13804-13809

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0702753104

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2007-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6136654

http://www.w3.org/2001/XMLSchema#string

P698

17702867

http://www.w3.org/2001/XMLSchema#string

P921

P932

1959463

http://www.w3.org/2001/XMLSchema#string